Fesoterodinefumarate
- CAS No.
- 286930-03-8
- Chemical Name:
- Fesoterodinefumarate
- Synonyms
- Toviaz;CS-102;CS-244;SPM 907;Spm 8272;SMP 8272;Unii-eos72165S7;Fesoterodinefumarate;PF-00695838 fumarate;Fesoterodine maleate
- CBNumber:
- CB51075581
- Molecular Formula:
- C30H41NO7
- Molecular Weight:
- 527.65
- MDL Number:
- MFCD12756004
- MOL File:
- 286930-03-8.mol
- MSDS File:
- SDS
| Melting point | 72-78°C |
|---|---|
| storage temp. | Inert atmosphere,2-8°C |
| solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) |
| form | Solid |
| color | White to Off-White |
| Stability | Hygroscopic |
| FDA UNII | EOS72165S7 |
| NCI Drug Dictionary | fesoterodine fumarate |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H361-H402-H319 | |||||||||
| Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P264-P280-P305+P351+P338-P337+P313P-P264-P270-P301+P312-P330-P501 | |||||||||
| NFPA 704 |
|
Fesoterodinefumarate price More Price(32)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 23777 | Fesoterodine (fumarate) ≥98% | 286930-03-8 | 1mg | $29 | 2024-03-01 | Buy |
| Cayman Chemical | 23777 | Fesoterodine (fumarate) ≥98% | 286930-03-8 | 5mg | $72 | 2024-03-01 | Buy |
| Cayman Chemical | 23777 | Fesoterodine (fumarate) ≥98% | 286930-03-8 | 10mg | $99 | 2024-03-01 | Buy |
| TRC | F321300 | (R)-FesoterodineFumarate | 286930-03-8 | 25mg | $145 | 2021-12-16 | Buy |
| TRC | F321300 | (R)-FesoterodineFumarate | 286930-03-8 | 50mg | $275 | 2021-12-16 | Buy |
Fesoterodinefumarate Chemical Properties,Uses,Production
Description
Fesoterodine fumarate is a new drug for the treatment of overactive bladder syndrome developed by Pfizer, which was approved by the US FDA in October 2008. Fesoterodine fumarate is a prodrug, which is rapidly hydrolyzed in blood after oral administration to 5-hydroxymethyl tolterodine (5-HMT), which is also the active metabolite of tolterodine.
Biological activity
Fesoterodine Fumarate (SPM 907) is a prodrug of the muscarinic receptor antagonist 5-hydroxymethyl tolterodine, used to treat overactive bladder.
Side effects
The most common side effects was dry mouth, which was observed in the placebo group, the product 4 in the Phase II and Phase III clinical trials (a total of 2 859 patients, 2 288 taking this product for 8 to 12 weeks). The incidences of dry mouth at mg/d and 8 mg/d were 7%, 19%, and 35%, respectively, and the incidences of drug discontinuation due to dry mouth were 0.4%, 0.4%, and 0.8%, respectively. The second most common adverse reaction was constipation. The incidence of constipation in the placebo group and the 4 mg/d and 8 mg/d groups of this product was 2%, 4% and 6%, respectively. Other reported adverse events included loss of appetite, nausea, epigastric pain, urinary tract infection, upper respiratory tract infection, dry eyes, dysuria, urinary retention, cough, peripheral edema, back pain, insomnia, abnormal liver function, and rash.
Chemical Properties
White Solid
Uses
(R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800).
Uses
Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv
Clinical Use
Antimuscarinic:Symptomatic treatment of urinary incontinence, frequency or urgency
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic
side effects with disopyramide.
Antifungals: dose reduction advised with
itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir,
indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic
plasma levels. Concomitant use with CYP3A4
inducers (e.g. carbamazepine, rifampicin,
phenobarbital, phenytoin, St John's Wort) is not
recommended.
Co-administration of a potent CYP2D6 inhibitor
may result in increased exposure and adverse events.
A dose reduction to 4 mg may be needed'
Metabolism
Rapidly and extensively hydrolysed to its active metabolite. The active metabolite is further metabolised in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine. Approximately 70% of an oral dose of fesoterodine is recovered in the urine as metabolites, and a smaller amount in the faeces.
Fesoterodinefumarate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Henan Bao Enluo International TradeCo.，LTD | +86-17331933971 +86-17331933971 | deasea125996@gmail.com | China | 2472 | 58 |
| Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | info@fdachem.com | China | 20283 | 58 |
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | sales@sjar-tech.com | China | 474 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21634 | 55 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29880 | 58 |
| Shaanxi Yikanglong Biotechnology Co., Ltd. | 17791478691 | yklbiotech@163.com | CHINA | 296 | 58 |
| Biochempartner | 0086-13720134139 | candy@biochempartner.com | CHINA | 965 | 58 |
| Hangzhou Cyanochem Co., Ltd. | +86 17788583750 | sales@cyanochem.com | CHINA | 281 | 58 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28172 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
View Lastest Price from Fesoterodinefumarate manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-12-25 | Fesoterodine Fumarate
286930-03-8
|
US $0.00 / g | 1g | More Than 99% | 50kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | |
 |
2024-12-13 | Fesoterodinefumarate
286930-03-8
|
US $0.00 / g | 1g | 99%~101% | 10kg/month | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2024-11-19 | Fesoterodine fumarate
286930-03-8
|
US $47.00-113.00 / mg | 98.55% | 10g | TargetMol Chemicals Inc. |
-
- Fesoterodine Fumarate
286930-03-8
- US $0.00 / g
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- Fesoterodinefumarate
286930-03-8
- US $0.00 / g
- 99%~101%
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Fesoterodine fumarate
286930-03-8
- US $47.00-113.00 / mg
- 98.55%
- TargetMol Chemicals Inc.